$82 Million Funds Off-The-Shelf and Personalized Cancer Vaccines

A corporate venture firm focused on investing in companies developing innovative solutions and ideas today announced its participation in an extension of the Series C financing round for Nouscom, a clinical-stage immuno-oncology company.

Nouscom raised approximately $82 million in its oversubscribed Series C round, which was first announced in November 2023.

Angelini Ventures joins a syndicate of top-tier international healthcare investors by participating in Nouscom’s financing.

This new financing will enable Nouscom, based in Basel, Switzerland. to continue advancing and expanding its wholly-owned clinical pipeline to achieve multiple clinical value catalysts, including:

• Readout from its ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf cancer vaccine for treating Mismatch Repair/Microsatellite Instable Metastatic Colorectal Cancer.
• Phase 1b study completion and progression of NOUS-209 monotherapy in Lynch Syndrome carriers investigating the potential to intercept, prevent, or delay cancer in high-risk individuals.
• Completion of the Phase 1b study for NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs.

Dr. Marina Udier, Chief Executive Officer at Nouscom, commented in a press release on March 21, 2024: “We are delighted to have extended our successful Series C financing round and excited to have Angelini Ventures on board. Their support strengthens our commitment to innovation and accelerates our journey towards delivering next-generation treatments for cancer patients.”